InnFocus, Inc. specializes in the development of innovative surgical solutions for glaucoma, leveraging a unique biomaterial known as SIBS (poly[styrene-block-isobutylene-block-styrene]). This advanced polymer was initially developed for cardiovascular applications but has been reformulated for ophthalmic use. SIBS is characterized by its remarkable biostability, which minimizes the risk of biodegradation and inflammation that can occur with conventional biomaterials. The design of SIBS, featuring a central polyisobutylene block capped with polystyrene, eliminates sites for degradation, ensuring longevity and functionality when implanted in the body.

The application of SIBS in glaucoma treatment involves the creation of microshunt devices that facilitate the drainage of aqueous humor, thereby reducing intraocular pressure. InnFocus was established in 2004 to focus on the development of these SIBS-based products, addressing unmet medical needs in the field of ophthalmology. The successful transition of SIBS from cardiology to ophthalmology underscores its versatility and potential to improve patient outcomes in glaucoma surgery.

United States

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries and regions. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

Santen Pharmaceutical Official Social Media Global Terms of Use​
https://www.santen.com/en/legal/

InnFocus

Company Details